Items in this sector ranged touched on topics such as pharma shipping, container technology, and sustainability.
At Pharma Commerce, cold chain transportation and storage has and continues to be a major area of coverage. Being that it is such a niche category, there is a bit of overlap between topics within the space—focus points include the latest advances in technology, net-zero goals for the sector, an overview of the industry, and much more.
Without further ado, below are top 5 cold chain pieces of the year.
5. Why Reliable Pharma Shipping Outweighs Cost
Service can trump price in pharma for a very basic reason—service failures related to transportation of goods have material consequences and associated risks. Optimal exception, given these constraints and regulations, challenges companies trying to balance service, cost, risk, and properly weighing the impact of each. These priorities, and the decisions behind any optimal execution strategy, must be based on the proper information to get it right, and that means—most fundamentally—a master data strategy.
4. Pharma Cold Chain in Search of Equilibrium
Unlike other impacted industries, the pandemic has spurred significant investment in capacities and services, due to the need to deliver vaccines and treatments expeditiously around the world. These investments will benefit the pharma logistics industry for a while to come, especially in the area of fragile, deep-frozen medicines, and treatments.
3. Reshaped Priorities Pave Cold Chain Path
In today’s increasingly interconnected world, the pharma industry is heavily reliant on efficient cold chain logistics and management to ensure temperature-sensitive products reach their destinations in perfect condition. Drug manufacturers are facing increasing challenges due to the rising value of pharmaceuticals and the growing complexity of biologics production.
2. Realistic Net-Zero Goals for Pharma
Taking into account the revenue generated by the pharma industry, as was done in a 2019 study, it can be deduced that the industry generates about 48.55 tons of CO2 equivalent per $1 million. This is 55% higher that the emission intensity of the automotive industry. With such demand for companies to meet the three pillars of the environmental, social, and governance (ESG) triad, many pharma organizations are reassessing their processes, and taking tangible actions to become more sustainable.
1. The State of the Pharma Cold Chain
Over the past decade, the industry practices associated with delivering temperature-sensitive pharmaceuticals have undergone a rapid evolution.All this was put severely to the test during the COVID-19 pandemic, and for the most part, the industry came through with flying colors, even though the leading vaccine offerings required a temperature regime (-80°C) that had only occasionally been seen previously. The various service providers for pharma cold chain distribution expanded their capacity and upgraded their service levels on a near-emergency basis—and those improvements are benefiting the pharma industry today.
Is Compounding the Answer to the Semaglutide Shortage? Experts Weigh In
October 30th 2024In this Q&A, Scott Brunner, CEO, and Tenille Davis, Chief Advocacy Officer, of the Alliance for Pharmacy Compounding discuss the challenges faced by patients and healthcare providers due to drug shortages, particularly for semaglutide and other medications.